In the present study, the differences in the tumor markers were evaluated among 78 cholangiocarcinoma patients based on the pathological stage before operation, and it was found that the patients at stage III had substantially higher levels of CA19-9, CA242, and CEA than those at stages I–II (p< 0.05). The gene discussed is CEACAM5; the disease is cholangiocarcinoma.